3'-Selenobisalanine" No Further a Mystery
All enrolled people who been given not less than a single dose of zosuquidar or placebo throughout induction have been monitored with the event of adverse situations (439 patients, 219 on zosuquidar and 210 on placebo). The most common adverse activities ended up associated with the period of prolonged and considerable myelosuppression as is antici